Pharmacokinetics of idarubicin in the isolated perfused rat lung: Effect of cinchonine and rutin

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 411-416

  Kuhlmann, Olaf ^a   Hofmann, Hans Stefan ^a   Müller, Sylvana P ^a   Weiss, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cinchonine; Idarubicin; Lung; Pharmacokinetics; Rutin

Indexed keywords

CINCHONINE; GLYCOPROTEIN P; IDARUBICIN; IDARUBICINOL; RUTOSIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG INFUSION; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG UPTAKE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATED LUNG; LUNG PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VEIN BLOOD FLOW;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMALARIALS; CINCHONA ALKALOIDS; DRUG INTERACTIONS; IDARUBICIN; LUNG; MALE; RATS; RATS, WISTAR; RUTIN; TIDAL VOLUME;

EID: 0041625861     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00004     Document Type: Article

References (31)

1. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13:2827-2834.
2. Colombo T, Gonzales PC, D'Incalci M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996; 73:866-871.
3. Furrer M, Lardinois D, Thormann W, et al. Isolated lung perfusion: single-pass system versus recirculating blood perfusion in pigs. Ann Thorac Surg 1998; 65:1420-1425.
4. Wang H-Y, Hochwald S, Ng B, Burt ME. Regional chemotherapy via pulmonary artery with blood flow occlusion in a solitary tumor nodule model. Anticancer Res 1996; 16:3749-3753.
5. Weksler B, Ng B, Lenert JT, Burt ME. Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection. Ann Thorac Surg 1993; 56:209-214.
6. Ng B, Hochwald, SN, Burt ME. Isolated lung perfusion with doxorubicin reduces cardiac and host toxicities associated with systemic administration. Ann Thorac Surg 1996; 61:969-972.
7. Touya JJ, Rahimian J, Corbus HF, et al. The lung as a metabolic organ. Semin Nucl Med 1986; 16:296-305.
8. Felsted RL, Gee M, Bachur NR. Rat liver daunorubicin reductase. An aldo-keto reductase. J Biol Chem 1974; 249:3672-3679.
9. Forrest GL, Gonzalez B. Carbonyl reductase. Chem-Biol Interact 2000; 129:21-40.
10. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24:275-288.
11. Lovless H, Arena E, Felsted RL, Bachur NR. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res1978; 38:593-598.
12. Hollingshead LM, Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 42:690-719.
13. Campbell L, Abulrob AN, Kandalaft LE, et al. Constitutive expression of P-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther 2003; 304:441-452.
14. Solary E, Mannone L, Moreau D, et al. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Leukemia 2000; 14:2085-2094.
15. Kuhlmann O, Hofmann S, Weiss M. Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography. J Chromatogr B 1999; 728:279-282.
16. Purves RD. Optimum numerical integration methods for estimation of area-under-the curve (AUC) and area-under-the-first-moment-curve (AUMC). J Pharmacokin Biopharm 1992; 20:211-226.
17. D'Argenio DZ, Sohumitzky A. ADAPT II User's guide Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles CA: Biomedical Simulations Resource; 1997.
18. Döring HJ, Dehnert H. Methoden zur Untersuchung der Atmungsorgane für die experimentelle Pharmakologie und Physiologie-Applikationen in vivo und in vitro. March-Hugstetten: Biomesstechnik-Verlag; 1997.
19. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997; 40:S3-S8.
20. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94:4028-4033.
21. Van Asperen J, Van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 1999; 79:108-113.
22. Genne P, Duchamp O, Solary E, Magnette J, Belon JP, Chauffert B. Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Des 1995; 10:103-118.
23. Cox DS, Scott KR, Gao H, Eddington ND. Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther 2002; 302:1096-1104.
24. Weiss M, Kang W. P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling. J Pharmacol Exp Ther 2002; 300:688-694.
25. Kang W, Weiss M. Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin. Pharm Res 2001; 18:1535-1541.
26. Kang W, Weiss M. Modeling the metabolism of idarubicinol in rat heart: Effect of rutin and phenobarbital. Drug Metab Disp 2003; 31:462-468.
27. Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994; 34:459-464.
28. Mitsunaga Y, Takanaga H, Matsuo H, et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000; 395:193-201.
29. Weiss M. Pharmacokinetics in organs and the intact body: model validation and reduction. Eur J Pharm Sci 1998; 7:119-127.
30. Kang W, Weiss M. Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart Effect of doxorubicin and hypothermia. Pharm Res 2003; 20:58-63.
31. Kang W, Weiss M. Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect. Naunyn-Schmiedeberg's Arch. Pharmacol 2003; 367:151-155.